Serum Biomarkers Can Differentiate Psoriatic Arthritis, Rheumatoid Arthritis
A serum protein biomarker panel can differentiate patients with early inflammatory arthritis with psoriatic arthritis from those with rheumatoid arthritis.
Spondyloarthritis
Secukinumab Approved for Enthesitis-Related Arthritis, Juvenile Psoriatic Arthritis
The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA.
Early Screening and Management of Cardiovascular Risk Factors Important in Psoriatic Arthritis and Ankylosing Spondylitis
Authors of the systematic review and meta-analysis aimed to determine the all-cause and cause-specific mortality in psoriatic arthritis and ankylosing spondylitis, based on available literature.
Two Doses of mRNA COVID-19 Vaccine Required to Induce Robust Immune Response in Patients With Inflammatory Joint Diseases
Researchers assessed the immune response of patients with rheumatoid arthritis and seronegative spondyloarthritis to mRNA COVID-19 vaccination after the first and second dose.
Upadacitinib Approved for Active Psoriatic Arthritis
The application is supported by data from two phase 3 studies (SELECT-PsA 1 and SELECT-PsA 2) that assessed upadacitinib in adults with active PsA.
Significant Improvements With Risankizumab in Patients With Psoriatic Arthritis
KEEPSAKE 2 is a clinical trial evaluating the efficacy and safety of risankizumab in patients with psoriatic arthritis.
Effect of the COVID-19 Pandemic on Psoriatic Disease
The effect of the COVID-29 pandemic on the hospital admissions and treatment adherences of patients with psoriasis are examined.
Guselkumab Improves Psoriatic Arthritis in Patients With Inadequate Response to TNFi
The phase 3 COSMOS study evaluated the efficacy and safety of guselkumab in 285 adults with active PsA who had an inadequate response to anti-tumor necrosis factors.
Early Diagnosis and Comprehensive Treatment Are Key to Adequate Care in Psoriatic Arthritis
The aim of the study was to evaluate the epidemiology, comorbidities, and risk factors for psoriatic arthritis, using a health insurance claims database.
Anti-IL-23 Therapy Effective in Improving Axial Inflammation in PsA, But Not axSpA?
Authors of a viewpoint discuss the lack of efficacy of anti-IL-23 therapy for axial spondyloarthritis, but the benefits of these medications in improving back pain symptoms induced by axial inflammation in psoriatic arthritis.
- Loading...
Loading...
Next post in Ankylosing Spondylitis
Loading... 
Loading...